Clinical Trials Browser

NIH × Interventional × ASTX-660 × Clear all

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma